Thirty outpatients of both sexes with endoscopic evidence of autonomous erosive duodenitis were randomly treated with either rioprostil* (a PGE1 derivative) 200 μg b.i.d or with sucralfate 1 g t.i.d for four weeks. Unhealed patients continued the ongoing treatment for a further 4-week period. Both drugs were found significantly effective in inducing relief of dyspeptic symptoms. At eight weeks complete disappearance of duodenal erosions was observed in 57.2% of patients on rioprostil and in 64.3% on sucralfate. No significant differences between the two drugs were found in either their clinical or endoscopic effectiveness. Neither diarrhoea nor other side-effects were reported with rioprostil, while nausea was experienced by two patients treated with sucralfate. Rioprostil proved to be a safe and effective therapeutic agent in gastroduodenal disorders where the use of cytoprotective drugs is required.
|Number of pages||5|
|Journal||Clinical Trials Journal|
|Publication status||Published - 1987|
- Erosive duodenitis
ASJC Scopus subject areas
- Pharmacology (medical)